Benjamin Margolis, MD
Pulmonary Disease · Bannockburn, ILNPI 1174600514
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.7% of the total across 61 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 17 manufacturers reported payments, led by AstraZeneca at 34.4% of the total.
Across 61 payments — averaging $63.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- Boehringer Ingelheim$473
- United Therapeutics Corporation$431
- Inspire Medical Systems, Inc.$297
- Pulmonx Corporation$283
- Harmony Biosciences LLC$164
- plus $883 from 11 others
Across 4 payments — averaging $21,753 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$64K
- Novartis$23K
What the payments were for
- Food & beverage$3,848100%
- Education$110%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 24 | $1,328 |
| Boehringer Ingelheim | 8 | $473 |
| United Therapeutics Corporation | 4 | $431 |
| Inspire Medical Systems, Inc. | 3 | $297 |
| Pulmonx Corporation | 2 | $283 |
| Harmony Biosciences LLC | 2 | $164 |
| Regeneron Healthcare Solutions, Inc. | 1 | $124 |
| GSK | 1 | $121 |
| Sanofi | 1 | $121 |
| Genentech USA, Inc. | 1 | $113 |
| Philips North America LLC | 6 | $112 |
| Salvin Dental Specialties, Inc. | 1 | $92 |
| Insmed, Inc. | 3 | $58 |
| Johnson & Johnson | 1 | $57 |
| 3b Medical, Inc. | 1 | $39 |
| La Jolla Pharmaceutical Company | 1 | $24 |
| Resmed Corp | 1 | $23 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FASENRA$610
- DUPIXENT$365
- CHARTIS CATHETER$283
- ZEPHYR ENDOBRONCHIAL VALVE$283
- PULMONX CHARTIS TABLET CONSOLE$283
- ZEPHYR DELIVERY CATHETER$283
- BREZTRI$244
- Inspire Upper Airway Stimulation System$240
- Wakix$123
- AIRSUPRA$121
- NUCALA$121
- OFEV$116
How this compares
$3,859 in reported general payments places this provider in the 65th percentile of 539 pulmonary disease providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 108 | $142,648 |
| Pirfenidone | 37 | $138,033 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 36 | $37,624 |
| Breo ElliptaFluticasone/Vilanterol | 30 | $26,115 |
| Arnuity ElliptaFluticasone Furoate | 41 | $24,403 |
| Spiriva RespimatTiotropium Bromide | 25 | $20,960 |
| Incruse ElliptaUmeclidinium Bromide | 24 | $14,540 |
| DuleraMometasone/Formoterol | 20 | $9,946 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 56 | $8,146 |
| SymbicortBudesonide/Formoterol Fumarate | 14 | $6,532 |
| Wixela InhubFluticasone Propion/Salmeterol | 43 | $6,520 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 11 | $5,970 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 140 | $4,893 |
| Fluticasone Propionate HfaFluticasone Propionate | 19 | $4,402 |
| Ventolin HfaAlbuterol Sulfate | 23 | $2,577 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Arnuity Ellipta, Incruse Ellipta | $121 | $245,329239 claims |
| Boehringer IngelheimSpiriva Respimat, Stiolto Respimat | $473 | $26,93036 claims |
| AstraZenecaSymbicort | $1,328 | $6,53214 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 539 pulmonary disease providers in Illinois.
Other pulmonary disease in Bannockburn
- Douglas HogarthChicago$2.9M
- Steven WhiteChicago$970K
- Momen WahidiChicago$779K
- Septimiu MurguChicago$633K
- Ayodeji AdegunsoyeChicago$561K
- Kristopher McDonoughJoliet$461K
- Ravi KalhanChicago$375K
- Brian GaribaldiChicago$356K
- Danish ThameemChampaign$353K
- Bradford BemissMaywood$259K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.